| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Urological Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892 [J. R. G.], and Howard Hughes Medical Institute, Ann Arbor, Michigan 48109-0650 [G. R. D.]
Renal cell carcinoma (RCC) is the most common malignancy in the adult kidney. Because RCC is generally thought to arise from the epithelium of the proximal tubules, the expression of Pax-2, a gene required for renal epithelium development, was examined in primary tumors and tumor-derived cell lines. Immunostaining of frozen sections from the primary tumors indicated Pax-2 expression in the malignant cells but not in the surrounding stroma. In a panel of human RCC-derived cell lines, 73% expressed Pax-2 protein and mRNA. Treatment of RCC cell lines with antisense oligodeoxynucleotides resulted in down-regulation of Pax-2 protein expression and growth inhibition after 3 days in culture. These data indicate that Pax-2 gene function is required for proliferation, as well as differentiation during embryonic development, and suggest a novel therapy for RCC.
1 To whom requests for reprints should be addressed, at Howard Hughes Medical Institute, 4510 MSRB I, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0650.
Received 5/10/95. Accepted 7/19/95.
This article has been cited by other articles:
|
|
 |
|
  A. H.T. Nguyen, M. Beland, Y. Gaitan, and M. Bouchard Calcineurin A-Binding Protein, a Novel Modulator of the Calcineurin-Nuclear Factor of Activated T-Cell Signaling Pathway, Is Overexpressed in Wilms' Tumors and Promotes Cell Migration Mol. Cancer Res., June 1, 2009; 7(6): 821 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V.-D. Luu, G. Boysen, K. Struckmann, S. Casagrande, A. von Teichman, P. J. Wild, T. Sulser, P. Schraml, and H. Moch Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., May 15, 2009; 15(10): 3297 - 3304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ozcan, J. Zhai, C. Hamilton, S. S. Shen, J. Y. Ro, B. Krishnan, and L. D. Truong PAX-2 in the Diagnosis of Primary Renal Tumors: Immunohistochemical Comparison With Renal Cell Carcinoma Marker Antigen and Kidney-Specific Cadherin Am J Clin Pathol, March 1, 2009; 131(3): 393 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonsato, S. Buttiglieri, M. Chiara Deregibus, B. Bussolati, E. Caselli, D. Di Luca, and G. Camussi PAX2 expression by HHV-8-infected endothelial cells induced a proangiogenic and proinvasive phenotype Blood, March 1, 2008; 111(5): 2806 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonsato, S. Buttiglieri, M. C. Deregibus, V. Puntorieri, B. Bussolati, and G. Camussi Expression of Pax2 in Human Renal Tumor-Derived Endothelial Cells Sustains Apoptosis Resistance and Angiogenesis Am. J. Pathol., February 1, 2006; 168(2): 706 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Buttiglieri, M. C. Deregibus, S. Bravo, P. Cassoni, R. Chiarle, B. Bussolati, and G. Camussi Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells J. Biol. Chem., February 6, 2004; 279(6): 4136 - 4143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Brophy, K. M. Lang, and G. R. Dressler The Secreted Frizzled Related Protein 2 (SFRP2) Gene Is a Target of the Pax2 Transcription Factor J. Biol. Chem., December 26, 2003; 278(52): 52401 - 52405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Edouga, B. Hugueny, B. Gasser, L. Bussieres, and K. Laborde Recovery after relief of fetal urinary obstruction: morphological, functional and molecular aspects Am J Physiol Renal Physiol, July 1, 2001; 281(1): F26 - F37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lechner, I. Levitan, and G. R. Dressler PTIP, a novel BRCT domain-containing protein interacts with Pax2 and is associated with active chromatin Nucleic Acids Res., July 15, 2000; 28(14): 2741 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Peters, B Wilm, N Sakai, K Imai, R Maas, and R Balling Pax1 and Pax9 synergistically regulate vertebral column development Development, January 12, 1999; 126(23): 5399 - 5408. [Abstract] [PDF]
|
|
|
|
|
|
C. K. Stayner, H. E. Cunliffe, T. A. Ward, and M. R. Eccles Cloning and Characterization of the Human PAX2 Promoter J. Biol. Chem., September 25, 1998; 273(39): 25472 - 25479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Krenacs, A. W. Himmelmann, L. Quintanilla-Martinez, T. Fest, A. Riva, A. Wellmann, E. Bagdi, J. H. Kehrl, E. S. Jaffe, and M. Raffeld Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas Blood, August 15, 1998; 92(4): 1308 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Walker Molecular Genetics of Renal Carcinogenesis Toxicol Pathol, January 1, 1998; 26(1): 113 - 120. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bernasconi, A. Remppis, W. J. Fredericks, F. J. Rauscher III, and B. W. Schafer Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins PNAS, November 12, 1996; 93(23): 13164 - 13169. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
